Monitor for the final offering size and pricing in the subsequent 424B5 filing. The dilutive impact will depend on the number of shares sold relative to the 27.6M shares outstanding. The company's cash runway extends into 2028 per the filing, but this raise suggests accelerated spending on clinical trials.
Price Chart
Executive Summary
Crescent Biopharma filed a preliminary prospectus supplement for an underwritten offering of ordinary shares and pre-funded warrants. The offering size and pricing are not yet disclosed, but the company had approximately $171.6M in cash as of June 30, 2026. This dilutive capital raise for a clinical-stage biotech with no revenue signals a need for additional funding to support clinical development of its pipeline (CR-001, CR-002, CR-003).
Key Facts
- Offering of ordinary shares and pre-funded warrants; terms (size, price) are preliminary and not yet disclosed.
- Company had approximately $171.6M in cash and cash equivalents as of June 30, 2026 (preliminary, unaudited).
- Stock closed at $15.69 on July 13, 2026; market cap ~$433M.
- Underwriters include Jefferies, TD Cowen, Guggenheim, Cantor, and LifeSci Capital.
- Company has a $200M ATM facility with Jefferies (dated July 1, 2026) but agreed not to sell under it until the earlier of full exercise of the underwriters' option or 30 days after this prospectus supplement.
- 60-day lock-up for officers, directors, and certain stockholders.
- Pre-funded warrants have an exercise price of $0.001 and do not expire until fully exercised.
Financial Impact
Undisclosed amount; offering will be dilutive to existing shareholders. Company had $171.6M cash as of June 30, 2026.
Risk Factors
- Offering size unknown but likely material relative to $433M market cap.
- Clinical-stage biotech with no revenue; all pipeline candidates are in early trials.
- Potential further dilution from the $200M ATM facility after the lock-up period.
- Pre-funded warrants may be exercised, adding to share count with minimal additional proceeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001628280-26-048144 |
| Document: 0001628280-26-048144-index-headers.html | 0001628280-26-048144 |
| Document: 0001628280-26-048144-index.html | 0001628280-26-048144 |
| Document: 0001628280-26-048144.txt | 0001628280-26-048144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 15, 2026 12d ago | Press Release | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $13.27 (−4.81%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $13.27 (−18.34%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $13.27 (−11.65%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $13.27 (−20.25%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $13.27 (+12.18%) |
Jul 14, 2026 15w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 14, 2026 15w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $13.27 (−15.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers